NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced data from the pivotal Phase 3 AXIS 1032 trial, showing that in patients with previously treated advanced renal cell carcinoma (RCC), axitinib significantly extended progression-free survival (PFS) [HR=0.665, 95% CI; P<0.0001], with a median PFS of 6.7 months (95%CI, 6.3-8.6), compared with 4.7 months (4.6-5.6) for those treated with sorafenib, a standard of care for this patient population. PFS was significantly longer in axitinib-treated

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced today that its New Drug Application (NDA) for crizotinib, an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor, has been accepted for filing and granted Priority Review status by the U.S. Food and Drug Administration (FDA) and has been filed with the Japanese Ministry of Health, Labour and Welfare (MHLW). The proposed indication is for the treatment of patients with ALK-positive advanced non-small cell lung cancer (NSCLC). “Our abilit

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. will present more than 30 abstracts, including data from investigational compounds, axitinib,1 crizotinib,2 and bosutinib,3 as well as data evaluating Sutent® (sunitinib malate), across multiple tumor types,4,5 at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from June 3-7. The Company will also share analyses from early stage compounds focused on the science behind tumor growth.6,7,8 “The research we are presenting

MADISON, N.J.--(BUSINESS WIRE)--Pfizer Animal Health and American Humane Association today announced a partnership to conduct a study on the impact of animal-assisted therapy on pediatric oncology patients, as well as on their parents, caregivers, siblings, and other close family members. The partnership — which includes a $282,000 grant from Pfizer and the Pfizer Foundation — exemplifies the strategic goal of both organizations to better quantify in clinical terms what many in health care alrea

NEW YORK--(BUSINESS WIRE)--Pfizer Inc., together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, is pleased to announce the Alzheimer’s Association™, the world's leading voluntary health organization in Alzheimer's care, support and research, as a new beneficiary of The 7 Summits Climb for Alzheimer’s: Memories are Everything campaign. Through this campaign, mountaineer and Alzheimer’s disease advocate Alan Arnette is seeking to climb the 7 Summit

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that the data from its two pivotal Phase 3 immunogenicity and safety trials of Prevnar 13®* (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]) in adults aged 50 years and older met all study endpoints. These studies provide the clinical foundation for the regulatory filings that have been submitted in the United States, the European Union and more than a dozen other countries. The results are being presented to

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. announced that Revatio® (sildenafil citrate) has been approved by the European Commission for the treatment of pediatric patients aged 1 to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary hemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease. “Pulmonary arterial hypertension is a rare, devastating disease that can

WASHINGTON--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from a Phase 3 12-week efficacy sub-study, which found that PRISTIQ® (desvenlafaxine), a serotonin-norepinephrine reuptake inhibitor (SNRI), significantly reduced the number and severity of moderate-to-severe hot flashes in postmenopausal women. The data were presented at the 59th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in Washington, D.C.1 PRISTIQ, which is approved by the U.S

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE):   ($ in millions, except per share amounts)   First-Quarter 2011     2010     Change Reported Revenues $ 16,502 $ 16,576 -- Adjusted Income(1) 4,808 4,862 (1 %) Adjusted Diluted EPS(1) 0.60 0.60 -- Reported Net Income(2) 2,222 2,026 10 % Reported Diluted EPS(2) 0.28 0.25 12 %                         See end of text prior to tables for notes.   Pfizer Inc. (NYSE: PFE) today reported financial results for first-quarter 2011. As a result of Pfizer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by David Simmons, President and General Manager, Emerging Markets and Established Products, at the Bank of America Merrill Lynch 2011 Healthcare Conference on Tuesday, May 10, 2011 at 11:20 a.m. Pacific Daylight Time. To view and listen to the webcast, visit our web site at www.pfizer.com and click on the “Bank of America Merrill Lynch 2011 Healthcare Conference” link